Benzinga | Jan 6, 2021 07:14AM EST

Goldman Sachs Downgrades Myovant Sciences to Neutral, Announces $30 Price Target

Goldman Sachs analyst Paul Choi downgrades Myovant Sciences (NYSE:MYOV) from Buy to Neutral and announces $30 price target.